Fig. 6.
The induction of cellular and humoral immune responses in animals treated with the PMLA-fusion nanobioconjugate. Blood samples were taken on day 27 after tumor inoculation from the tail vein from mice bearing D2F2/E2 tumors treated with buffer, the antibody–cytokine fusion protein, or the PMLA-fusion nanobioconjugate. Pooled samples were tested for mouse anti-HER2/neu IgG1 (A) as a marker of the induction of a TH2 response and IgG2a (B) as a marker for the induction of a TH1 response by ELISA. IgG1 level was determined using sera diluted 1:300 and IgG2a level was determined using sera diluted 1:100. Values represent the average of triplicate determinations of pooled serum aliquots and error bars indicate the standard deviation. Significant differences were determined using the Student's t-test (**) of p < 0.01 and (*) p < 0.05.